T15 Pharma Buyout Map: 29 Deals, ~$98B, and Who Has Room for More

We mapped 29 buyouts announced in 2026 across the T15 players, representing ~$98B in disclosed potential deal value.

Lilly leads with 13 buyouts (45% of the group total). Oncology and I&I account for roughly two-thirds of transactions and 72% of deal value. Modality is more distributed: small molecules and antibody-based therapies account for 34%, followed by vaccines and cell therapy at 10% each, with the remaining 10% for target-enabling tech. Just 3 targets (Arcellx, Nuvalent, Crinetics) had a lead asset under regulatory review or already marketed at announcement; Phase 1 was the most common development stage at the time of deal (~28%). Novo, Pfizer, BMS and Sanofi haven't announced any buyouts this year, but all have either done major recent deals or been active via licensing.

Based on Q2 earnings and a ~3x gross debt / EBITDA leverage ceiling, pharma still has plenty of capacity (median of ~$24B). High capacity (>$50B): Lilly, J&J, Roche, Novo. Medium ($15-50B): Novartis, AstraZeneca, Sanofi, BMS, Gilead, AbbVie, Vertex. Lower (<$15B): GSK, Pfizer, Amgen, Merck.

The more interesting question is how that capacity lines up with need for new revenue. J&J has the clearest combination of need and capacity, with ~$40B of existing revenue exposed to LOEs over the next 5 years, ~20% covered by acquired peak sales estimates and ~$80B of acquisition capacity. Conversely, Merck has ~$47B exposed (mostly Keytruda), ~25% covered but only ~$12B of capacity. There's more nuance as you factor in internal growth and potential from licensing and collaboration deals, but generally pharma can have similar replacement needs and very different BD strategies.

Lilly has an unusual opportunity to get ahead of the LOE treadmill. It gained early visibility into how enormous GLP-1 sales would be, creating a free-cash-flow machine until the 2030s. That provides breathing room to place many more bets across early-stage programs, tech and modalities. Pharma has always been structured like a VC, but Lilly is really operating like one. The eventual cliff will be unprecedented, but the bet is that investing aggressively now will create the broad revenue base needed to grow beyond it.